Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction.In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and...
Paper Details
Title
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Published Date
Oct 8, 2020
Volume
383
Issue
15
Pages
1413 - 1424
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History